Hearscape
← Therapeutics
Details checkedStatus confirmedHistorical/discontinuedCheckedcompany

OTO-825 by Otonomy

Also known as: OTO-825

Otonomy

Primary source
Company
Otonomy
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Preclinical
Status
Discontinued
Target Gene
GJB2
Route / Mode
Intracochlear injection
Confidence
87%
Status Confidence
Status confirmed
Evidence Strength
Needs more support
Last Reviewed
2026-05-31
Geography
United States
Population
pediatric, congenital, genetic, pre-lingual
Trial IDs
0
Mechanism

AAV-based gene therapy program designed to restore hearing in patients with GJB2 mutation-associated congenital hearing loss.

Indications
Hearing LossSensorineural Hearing LossGenetic Hearing Loss
Notes

Preclinical GJB2 asset that became strategically important as one of the early AAV hearing-loss contenders, but development visibility ended with Otonomy's wind-down.

Evidence & Sources
3 structured sources
company
Supports: canonicalName, aliases, company, allCompanies, mechanism, targetGene, indications
IDs: OTO-825
Open
company
Supports: stage, route, populationTags, notes
IDs: OTO-825
Open
company
Supports: status, notes
IDs: Otonomy
Open
Key Events
2021-04-28
Otonomy and AGTC presented preclinical proof-of-concept data for OTO-825
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2